Nuvalent ($NUVL) Acquired by GSK
for $10.6 Billion

Executive Summary

In the early hours of Tuesday, June 9, 2026, GSK plc announced the acquisition of Nuvalent, Inc. (Nasdaq: NUVL) in an all-cash transaction valued at approximately $10.6 billion, representing $124 per share — a 40% premium to the prior closing price. Net of acquired cash, GSK’s aggregate investment is estimated at approximately $9.4 billion, funded primarily through debt.

The deal is GSK’s largest oncology acquisition in over a decade and represents CEO Luke Miels’ first major strategic move since taking the helm, as he works to drive the British pharmaceutical group toward a stated revenue target of more than £40 billion by 2031. Nuvalent brings one of the most compelling precision oncology pipelines in non-small cell lung cancer (NSCLC): two next-generation selective kinase inhibitors — neladalkib (NVL-655, ALK+) and zidesamtinib (NVL-520, ROS1+) — both with NDAs under FDA review, plus an early-stage HER2 inhibitor program.

Deal Terms

The deal is structured as a fully cash-financed acquisition with no equity component. GSK expects the transaction to be additive to sales and operating profit beginning in 2027, and to contribute to core EPS growth by 2029. Closing is subject to customary regulatory approvals and Nuvalent shareholder approval.

GSK CEO Luke Miels stated the acquisition offers “significant new treatment options” for lung cancer patients and creates a platform to expand Ris-Rez, GSK’s experimental antibody-drug conjugate currently in late-stage testing, by combining it with Nuvalent’s molecular targets.

Nuvalent Pipeline: What GSK Is Buying

Nuvalent built its pipeline around next-generation kinase inhibitors for molecularly-defined NSCLC. At the time of the deal, two principal assets are already under FDA review with complete regulatory dossiers.

NVL-520 / Zidesamtinib — First Asset at PDUFA

Zidesamtinib is designed to address the primary clinical challenges in ROS1+ patients: emergent TKI resistance, CNS-related adverse events, and brain metastases. The FDA accepted the NDA for adults with locally advanced or metastatic ROS1-positive NSCLC previously treated with at least one ROS1 TKI. PDUFA: September 18, 2026. Nuvalent had also been developing a TKI-naive label expansion through the ARROS-1 Phase 2 trial, now in GSK’s hands.

NVL-655 / Neladalkib — The Flagship ALK Asset

Neladalkib is an ALK-selective, TRK-sparing, brain-penetrant inhibitor with FDA Breakthrough Therapy designation. Pivotal data from ALKOVE-1 (253 ALK+ TKI-pretreated patients), published in November 2025, demonstrated:

The NDA for neladalkib was submitted on April 7, 2026. The FDA granted Priority Review with a PDUFA target action date of November 27, 2026. Neladalkib also holds Breakthrough Therapy designation (granted May 2024 for ALK+ patients with ≥2 prior TKIs). The ASCO oral presentation on May 29 publicly confirmed the clinical data package. The Phase 3 ALKAZAR trial (neladalkib vs alectinib in TKI-naive front-line setting) is ongoing and represents the path to a significantly larger commercial label.

Why GSK Bought Nuvalent

The strategic logic of the deal operates on three distinct levels.

1. Filling the Oncology Gap

CEO Luke Miels was appointed with the explicit mandate to drive GSK past £40 billion in revenues by 2031. The HIV drug dolutegravir — a major revenue pillar — faces patent expiry in 2028. Oncology, and specifically NSCLC (the cancer indication with the largest pharmacologically-treated patient population), is the most logical vector to compensate that loss. With Nuvalent, GSK enters with two drugs potentially on market in 2026–2027 and an ongoing Phase 3.

2. Synergy with Ris-Rez

GSK is developing Ris-Rez, an antibody-drug conjugate (ADC) currently in late-stage clinical testing. ADCs perform best when combined with selective molecular inhibitors: Nuvalent’s ALK and ROS1 targets create potentially testable combinations with Ris-Rez, broadening the commercial scope of both products.

3. Speed vs. Internal R&D

Building a precision oncology program internally to the level of neladalkib would require years and billions in R&D with uncertain outcomes. Buying Nuvalent with two NDAs already under review and a proven clinical team is, at $124/share, a capital allocation efficiency decision — despite the apparently steep premium.

Nuvalent Financial Snapshot (Pre-Deal)

Nuvalent was one of the few mid-cap biotechs with a robust cash position relative to burn rate and multiple assets simultaneously under regulatory review. The fact that the cash provided operational visibility through 2029 had effectively eliminated the near-term dilution risk that plagues many comparable companies, making the stock attractive both as a standalone investment and as an M&A target.

Sector Implications

The NUVL/GSK deal is not isolated: it is the second major oncology acquisition in a few months (following RAPT) and arrives in a context where large pharma is accelerating M&A strategy to address the 2026–2028 patent cliff. Key implications:

Names to watch as potential comparables or indirect sentiment beneficiaries in precision oncology M&A: $ELVN (Enliven, CML), $LEGN (Legend Biotech, multiple myeloma), $MERUS (bispecifics), $RXDX (ROS1/NTRK). None are direct comparables to NUVL, but the speculative re-rating following a large deal often touches the broader sub-sector.

Context: The May 25 Merlintrader Analysis

On May 25, 2026, Merlintrader published a three-catalyst analysis (NUVL, LEGN, ZBIO) describing NUVL as the cleanest setup of the three — mature regulatory positioning, NDA already under review, and ASCO data expected as public confirmation of the clinical package. The stock was trading around $102 with a market cap of approximately $8 billion. When GSK announced the $124 offer, readers who had followed that analysis had the context to understand both the asset value and the logic behind the premium paid.

Bottom Line

Nuvalent was acquired with a clear strategic rationale: two NDAs under FDA review, Breakthrough Therapy designation on neladalkib, a strong cash position, a credible management team, and a precision pipeline in NSCLC — the oncology indication with the highest therapeutic and commercial priority. GSK paid 40% to eliminate remaining regulatory uncertainty and acquire speed to market.

For NUVL shareholders positioned before the announcement: the deal is all-cash at $124 with no equity component. The M&A trade is closed. For those watching the sector more broadly: the zidesamtinib PDUFA on September 18, 2026 will now be followed as a validation event for the deal itself — an FDA approval would retroactively reinforce GSK’s valuation; a CRL would put it into question.